Competitors in the field are upadacitinib (JAK1 inhibitor) with a positive phase II trial in ulcerative colitis and filgotinib, another JAK inhibitor, which has been successful in Crohn’s disease, but no data for ulcerative colitis are available. Here, JAK1 is linked to ulcerative colitis.